NPS Pharmaceuticals, Inc.
Edit Page
Report
Scan day: 12 February 2014 UTC
17
Virus safety - good
Description: Discovers and develops drugs targeting skeletal, endocrinological, gastrointestinal, and central nervous system. Includes glossary, stages in pipeline, careers in North America, and investment in Salt Lake City, Utah. (Nasdaq: NPSP).
A Passionate Commitment to Rare Disorders NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/b (teduglutide [rDNA origin]) for injection for subcutaneous use is approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates.
Size: 1001 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Home |
| Keywords: | |
| Description: | |
| IP-address: | 64.78.146.38 |
WHOIS Info
| NS | Name Server: NS53.WORLDNIC.COM Name Server: NS54.WORLDNIC.COM |
| WHOIS | Status: clientTransferProhibited |
| Date | Creation Date: 26-apr-1995 Expiration Date: 27-apr-2015 |